LEXINGTON, Mass., April 11, 2018 /PRNewswire/ -- Agenus
Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
that three abstracts were accepted for presentation at the AACR
2018 Annual Meeting in Chicago
from April 14-18, 2018.
Agenus will present on pharmacodynamic data from a phase 1 trial
of a proprietary combination of AGEN1884 (anti-CTLA-4 antibody)
with AGEN2034 (anti-PD-1 antibody); preclinical data on
INCAGN02390, a novel antagonist antibody that targets the
co-inhibitory receptor TIM-3; and preclinical data on INCAGN02385,
an antagonist antibody targeting the co-inhibitory receptor
LAG-3.
Poster Presentation Details:
- Clinical pharmacodynamics data
Poster Title: Evaluation of Peripheral T-Cell Subset
Proliferation as a Pharmacodynamic Assay to Guide the Development
of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With
Solid Tumors
Poster Number: CT104 / 25
Session Date: April 16, 2018
Session Time: 1:00 PM - 5:00
PM
- Preclinical data on TIM-3 and LAG-3
Poster Title: INCAGN02390, a Novel Antagonist Antibody That Targets
the Co-Inhibitory Receptor TIM-3
Poster Number: 3825 / 15
Session Date: April 17, 2018
Session Time: 8:00 AM - 12:00
PM
Poster Title: INCAGN02385 Is an Antagonist Antibody Targeting the
Co-Inhibitory Receptor LAG-3 for the Treatment of Human
Malignancies
Poster Number: 3819 / 9
Session Date: April 17, 2018
Session Time: 8:00 AM - 12:00
PM
Agenus has licensed exclusive worldwide development and
commercialization rights for INCAGN02390 and INCAGN02385 to Incyte
Corporation. The licensed antibodies AGEN1884 and AGEN2034 were
originally developed under a Collaborative Research and Development
Agreement between Ludwig Cancer Research, 4-Antibody AG (now Agenus
Switzerland Inc.) and Recepta Biopharma S.A. AGEN1884 and AGEN2034
are partnered with Recepta Biopharma S.A. for certain South
American rights. Abstracts and posters will become available on the
Company's website
at http://agenusbio.com/technology/publications/ following
the poster sessions.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA.
For more information, please visit www.agenusbio.com;
information that may be important to investors will be routinely
posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' planned
poster presentations at AACR. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by
law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/three-agenus-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-aacr-2018-annual-meeting-300628124.html
SOURCE Agenus Inc.